Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caroline Boulton"'
Autor:
Adoke Yeka, Judith Straimer, Guoqin Su, Martin P. Grobusch, Kwaku Poku Asante, Vinay Kumar Venishetty, Sarfaraz Sayyed, Stephen Asiimwe, Gilles F. Ndayisaba, Sarita Barsainya, Abraham Oduro, Caroline Boulton, Henry Mugerwa, Esther K. Schmitt, Etienne Karita, Katalin Csermak Renner, Seydou Doumbia, P. Gandhi, Ivan Demin, Bakary Fofana
Publikováno v:
Clinical infectious diseases. Oxford University Press
Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d24df7b3925eb85fe952adea3a862
https://pubmed.ncbi.nlm.nih.gov/34410358
https://pubmed.ncbi.nlm.nih.gov/34410358
Autor:
Stuart J. Pocock, Alexander R. Lyon, Daniel M. Bloomfield, Amany El-Gazayerly, Claudio Gimpelewicz, Faiez Zannad, Piotr Ponikowski, Warren Sherman, Fady I. Malik, Wendy Gattis Stough, Marco Metra, Anna Baczynska, Krishna Prasad, Karsten Bruins Slot, Caroline Boulton, Jose Lopez-Sendon, Pieter A. de Graeff, Maureen Cronin, Ian Laws, Isabelle Richard-Lordereau, Benoit Tyl, Karl Swedberg, Stefan D. Anker, Salim Janmohamed, Gerasimos Filippatos, Martin R. Cowie, Lothar Roessig, Heidi Janssen, Santiago Figueroa Perez, Martin Lefkowitz, Pieter A. Doevendans, Marc A. Pfeffer, Giuseppe M.C. Rosano, Narimon Honarpour, Maria Borentain, Albert M. Kim, Maria Angeles Alonso Garcia, John J.V. McMurray, Dominik Lautsch
Publikováno v:
European Journal of Heart Failure. 19:718-727
Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure patients is characterized by a reduction in life expectancy, a progressive decline in health-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8f01ad99121884291aec9c2fad3ab50
https://doi.org/10.1002/ejhf.809
https://doi.org/10.1002/ejhf.809
Autor:
Ian, Graham, Chuck, Shear, Pieter, De Graeff, Caroline, Boulton, Alberico L, Catapano, Wendy Gattis, Stough, Stefan C, Carlsson, Guy, De Backer, Joseph, Emmerich, Scott, Greenfeder, Albert M, Kim, Dominik, Lautsch, Tu, Nguyen, Steven E, Nissen, Krishna, Prasad, Kausik K, Ray, Jennifer G, Robinson, William J, Sasiela, Karsten, Bruins Slot, Erik, Stroes, Tom, Thuren, Bart, Van der Schueren, Maja, Velkovski-Rouyer, Scott M, Wasserman, Olov, Wiklund, Emmanouil, Zouridakis, Cathrine, Thorstensen
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy, 4(2). Oxford University Press
The very high occurrence of cardiovascular events presents a major public health issue because treatment remains suboptimal. Lowering low-density lipoprotein cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7cf81c7f2a5f838f13a85da28ee0952
https://doi.org/10.1093/ehjcvp/pvx031
https://doi.org/10.1093/ehjcvp/pvx031
Publikováno v:
Contemporary Clinical Trials
Introduction The increasing complexities of conducting multiregional trials and an evolving regulatory environment contribute to unprecedented new challenges for use of patient-reported outcome measures (PROMs) 1 within clinical trials. This paper pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c40f1c616427ad54886ad0a865562e0
https://doi.org/10.1016/j.cct.2013.02.006
https://doi.org/10.1016/j.cct.2013.02.006